PE20211378A1 - Compuestos heterociclicos y de heteroarilo para tratar la enfermedad de huntington - Google Patents

Compuestos heterociclicos y de heteroarilo para tratar la enfermedad de huntington

Info

Publication number
PE20211378A1
PE20211378A1 PE2020002185A PE2020002185A PE20211378A1 PE 20211378 A1 PE20211378 A1 PE 20211378A1 PE 2020002185 A PE2020002185 A PE 2020002185A PE 2020002185 A PE2020002185 A PE 2020002185A PE 20211378 A1 PE20211378 A1 PE 20211378A1
Authority
PE
Peru
Prior art keywords
heterocyclic
heteroaryl compounds
huntington disease
treat huntington
compounds
Prior art date
Application number
PE2020002185A
Other languages
English (en)
Inventor
Nadiya Sydorenko
Md Rauful Alam
Michael A Arnold
Suresh Babu
Anuradha Bhattacharyya
Guangming Chen
Aleksey I Gerasyuto
Gary Mitchell Karp
Andrew J Kassick
Anthony R Mazzotti
Young-Choon Moon
Jana Narasimhan
Jigar Patel
Anthony Turpoff
Matthew G Woll
Wuming Yan
Nanjing Zhang
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of PE20211378A1 publication Critical patent/PE20211378A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Esta referido a compuestos de Formula I, en donde: R1 es cicloalquilo, heterociclilo C3-10-carbonilo; R2 es fenilo, heterociclilo, heteroarilo; W1 es C-Ra, CH-Ra, N, N-Rb, O, S; W2 es C-Ra, CH-Ra, N, N-Rb; W3 es C, CH, N; W4 y W5 son C-Ra o N. entre los compuestos preferidos tenemos los siguientes: 5-(1H-pirazol-4-il)-2-[1-(2,2,6,6-tetrametilpiperidin-4-il)-1H-imidazo[4,5-b]pirazin-5-il]fenol; 5-[2,5-difluoro-4-(1H-pirazol-4-il)fenil]-1-(2,2,6,6-tetrametilpiperidin-4-il)-1H-imidazo[4,5-b]pirazina; 5-(1H-pirazol-4-il)-2-[7-(2,2,6,6-tetrametilpiperidin-4-il)-7H-imidazo[4,5-c]piridazin-3-il]fenol; entre otros. Estos compuestos se emplean para tratar o mejorar la enfermedad de Huntington.
PE2020002185A 2018-06-27 2019-06-25 Compuestos heterociclicos y de heteroarilo para tratar la enfermedad de huntington PE20211378A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862690653P 2018-06-27 2018-06-27
PCT/US2019/038889 WO2020005873A1 (en) 2018-06-27 2019-06-25 Heterocyclic and heteroaryl compounds for treating huntington's disease

Publications (1)

Publication Number Publication Date
PE20211378A1 true PE20211378A1 (es) 2021-07-27

Family

ID=67180896

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020002185A PE20211378A1 (es) 2018-06-27 2019-06-25 Compuestos heterociclicos y de heteroarilo para tratar la enfermedad de huntington

Country Status (17)

Country Link
US (1) US11858941B2 (es)
EP (1) EP3814357B1 (es)
JP (1) JP7421507B2 (es)
KR (1) KR20210042265A (es)
CN (1) CN112654625A (es)
AR (1) AR119651A1 (es)
AU (2) AU2019294478B2 (es)
BR (1) BR112020026545A2 (es)
CA (1) CA3103976A1 (es)
CL (3) CL2020003378A1 (es)
CO (1) CO2020016285A2 (es)
EA (1) EA202092896A1 (es)
IL (1) IL279688A (es)
MX (1) MX2020014098A (es)
PE (1) PE20211378A1 (es)
SG (1) SG11202012674PA (es)
WO (1) WO2020005873A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3386511T (lt) 2015-12-10 2021-08-25 Ptc Therapeutics, Inc. Hantingtono ligos gydymo būdai
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
EP3645121A4 (en) 2017-06-28 2021-03-17 PTC Therapeutics, Inc. HUNTINGTON'S DISEASE TREATMENT METHODS
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
BR122020005073A2 (pt) 2017-08-04 2020-10-13 Skyhawk Therapeutics, Inc. Composto, composição farmacêutica e uso do composto
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
US20210009590A1 (en) 2018-03-27 2021-01-14 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
EP3814357B1 (en) 2018-06-27 2024-05-01 PTC Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
EP3814360A1 (en) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
KR20210135241A (ko) 2019-02-05 2021-11-12 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN113840602A (zh) * 2019-03-15 2021-12-24 斯基霍克疗法公司 用于校正异常剪接的组合物和方法
EP4219466A1 (en) * 2019-05-13 2023-08-02 PTC Therapeutics, Inc. Compunds for treating huntington's disease
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
KR20220093335A (ko) 2019-11-01 2022-07-05 노파르티스 아게 헌팅턴병의 진행을 늦추는 치료를 위한 스플라이싱 조절제의 용도
JP2023532623A (ja) 2020-05-13 2023-07-31 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチントン病を処置するためのｈｔｔモジュレータ
WO2022006550A1 (en) 2020-07-02 2022-01-06 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
EP4178963A1 (en) 2020-07-02 2023-05-17 Remix Therapeutics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2022060944A1 (en) * 2020-09-16 2022-03-24 Skyhawk Therapeutics, Inc. Compositions for modulating splicing
WO2022060943A1 (en) * 2020-09-16 2022-03-24 Skyhawk Therapeutics, Inc. Compositions for modulating splicing
WO2022060951A1 (en) * 2020-09-16 2022-03-24 Skyhawk Therapeutics, Inc. Compositions for modulating splicing
IL302839A (en) * 2020-11-12 2023-07-01 Ptc Therapeutics Inc A novel RNA transcript
IL302718A (en) 2020-11-13 2023-07-01 Ptc Therapeutics Inc A tablet for use in the treatment of Huntington's disease and a method for its preparation
CN116997555A (zh) * 2021-03-17 2023-11-03 豪夫迈·罗氏有限公司 新颖噻吩并嘧啶酮衍生物
TW202304446A (zh) 2021-03-29 2023-02-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
AR126612A1 (es) 2021-07-30 2023-10-25 Ptc Therapeutics Inc Compuestos de heteroarilo para el tratamiento de la enfermedad de huntington
WO2023081859A1 (en) * 2021-11-04 2023-05-11 Skyhawk Therapeutics, Inc. Triazine amino derivatives for treating sca3
WO2023220134A1 (en) * 2022-05-10 2023-11-16 Foghorn Therapeutics Inc. Pyrazine derivatives and uses thereof
WO2023244996A2 (en) * 2022-06-15 2023-12-21 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (es) 1963-04-04 1900-01-01
US3558618A (en) 1968-04-01 1971-01-26 Dow Chemical Co Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones
GB1383409A (en) 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
US4122274A (en) 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
US4342870A (en) 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
JPS56150091A (en) 1980-03-28 1981-11-20 Janssen Pharmaceutica Nv 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture
FR2567518B1 (fr) 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
US5089633A (en) 1987-04-28 1992-02-18 Georgia Tech Research Corporation Substituted isocoumarins
US5599816A (en) 1990-05-02 1997-02-04 Abbott Laboratories Quinolizinone type compounds
AU4231293A (en) 1992-05-13 1993-12-13 E.I. Du Pont De Nemours And Company Substituted pyrido(1,2-A)pyrimidinone derivatives as fungicides
EP0698092B1 (en) 1993-05-11 2007-07-25 The University Of North Carolina At Chapel Hill Antisense oligonucleotides which combat aberrant splicing and methods of using the same
JPH11510478A (ja) 1995-06-06 1999-09-14 アボツト・ラボラトリーズ キノリジノン型化合物
US5916916A (en) 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
US5869500A (en) 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
CA2269561C (en) 1998-04-22 2007-06-05 Dainippon Ink And Chemicals, Inc. Naphthalene derivative and liquid crystal composition comprising the same
AU5991699A (en) 1998-09-21 2000-04-10 Biochem Pharma Inc. Quinolizinones as integrin inhibitors
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6210892B1 (en) 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
EP1227084B1 (en) 1999-10-28 2005-12-14 Trine Pharmaceuticals, Inc. Drug discharge pump inhibitors
EP1857443B1 (en) 2000-01-24 2012-03-28 AstraZeneca AB Therapeutic morpholino-substituted compounds
ATE544473T1 (de) 2000-11-09 2012-02-15 Cold Spring Harbor Lab Chimäre moleküle zur modulation der genexpression
US6774134B2 (en) 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
BR0116411A (pt) 2000-12-21 2003-11-11 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
JPWO2002087589A1 (ja) 2001-04-26 2004-08-12 第一製薬株式会社 薬剤排出ポンプ阻害薬
AU2002364536B2 (en) 2001-12-07 2008-10-23 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as GSK-3 inhibitors
GB0205281D0 (en) 2002-03-06 2002-04-17 Novartis Ag Organic compounds
CA2493458A1 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
AU2003262833A1 (en) 2002-08-23 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent glycosides and methods for their use
ATE426602T1 (de) 2002-09-30 2009-04-15 Neurosearch As 1,4-diazabicycloalkanderivate, deren herstellung und verwendung
US20070078144A1 (en) 2003-01-29 2007-04-05 Stockwell Brent R Agents for treating neurodegenerative diseases
AU2004249730A1 (en) 2003-06-20 2004-12-29 Novartis Vaccines And Diagnostics, Inc. Pyridino(1,2-A)pyrimidin-4-one compounds as anticancer agents
GB0315494D0 (en) 2003-07-02 2003-08-06 Biofocus Plc Compounds which bind to the active site of protein kinase enzymes
CN1829709A (zh) 2003-08-01 2006-09-06 健亚生物科技公司 对抗黄病毒的双环咪唑衍生物
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US7309699B2 (en) 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
US7655657B2 (en) 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137203A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-quinuclidinyl amino-substituted biaryl derivatives
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
ES2360222T3 (es) 2003-12-24 2011-06-02 Biota Scientific Management Pty. Ltd. Agentes policíclicos para el tratamiento de infecciones respiratorias por virus sincicial.
SE0400184D0 (sv) 2004-01-30 2004-01-30 Fyrkloevern Scandinavia Ab New therapeutical use
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
CN1964717A (zh) 2004-04-08 2007-05-16 神经能质公司 经取代∴啉－4－基胺
WO2005105801A1 (en) 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
WO2006078834A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
US7879992B2 (en) 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
JP2006219453A (ja) 2005-02-14 2006-08-24 Tokyo Univ Of Pharmacy & Life Science キノリン環を母核とする金属識別型二波長性蛍光分子
US7563601B1 (en) 2005-06-01 2009-07-21 City Of Hope Artificial riboswitch for controlling pre-mRNA splicing
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
CN103110635A (zh) 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
US8258109B2 (en) 2005-10-20 2012-09-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of LMNA expression
KR101789603B1 (ko) 2005-11-10 2017-11-21 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Ｔｎｆ 수퍼패밀리 수용체에 대한 스플라이스 스위칭올리고머 및 염증성 질환 치료용 약제학적 조성물
RU2008110911A (ru) 2005-12-06 2010-01-20 Ньюросерч А/С (DK) Новые диазабициклические арильные производные и их медицинское применение
US20070197509A1 (en) 2005-12-21 2007-08-23 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
EP3210633B1 (en) 2006-01-26 2019-06-19 Ionis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
US8129515B2 (en) 2006-01-27 2012-03-06 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
JP2009531376A (ja) 2006-03-28 2009-09-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー ヒスタミンｈ３受容体活性を有するベンゾチアゾール
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
US20080247964A1 (en) 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
WO2007133756A2 (en) * 2006-05-15 2007-11-22 Neurogen Corporation Crf1 receptor ligands comprising heteroaryl fused bicycles
EP2029607A1 (en) 2006-05-23 2009-03-04 NeuroSearch A/S Novel 8,10-diaza-bicycloý4.3.1¨decane derivatives and their medical use
EP2079724B1 (en) 2006-07-20 2010-05-26 Amgen Inc. Substituted pyridone compounds and methods of use
US8337941B2 (en) 2006-07-27 2012-12-25 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
DK2066653T3 (da) 2006-08-03 2012-12-10 Rottapharm Spa 6-1H-Imidazoquinazolin- og -quinolinderivater, nye stærke analgetika og antiinflammatoriske midler
MX2009003892A (es) 2006-10-25 2009-04-23 Neurosearch As Compuestos de oxadiazol y tiadiazol y su uso como moduladores del receptor de acetilcolina nicotinico.
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
DK2114903T3 (da) 2006-12-22 2011-04-18 Avexa Ltd Bicykliske pyrimidinoner og anvendelser deraf
US20080171792A1 (en) 2006-12-28 2008-07-17 Jobdevairakkam Christopher New Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders
FR2914188B1 (fr) 2007-03-28 2012-06-22 Trophos Nouvelle composition a base d'oxime de cholest-4-en-3-one
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
CA2700841A1 (en) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
PL2193133T3 (pl) 2007-09-27 2016-01-29 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Imidazolotiadiazole do stosowania jako inhibitory kinazy białkowej
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009126635A1 (en) 2008-04-09 2009-10-15 Abbott Laboratories 2-amino-benzothiazole derivates useful as inhibitors of rock kinases
WO2009131958A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
US8633019B2 (en) 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
KR20110036583A (ko) 2008-06-20 2011-04-07 로타팜 에스.피.에이. 6-1ｈ-이미다조-퀴나졸린 및 퀴놀린 유도체, 신규 ｍａｏ 억제제 및 이미다졸린 수용체 리간드
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
WO2010000032A1 (en) 2008-07-02 2010-01-07 Avexa Limited Compounds having antiviral properties
WO2010019236A1 (en) 2008-08-13 2010-02-18 Ptc Therapeutics, Inc Methods for treating spinal muscular atrophy
WO2010024903A1 (en) 2008-08-29 2010-03-04 Yangbo Feng BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS
JP2012505898A (ja) 2008-10-16 2012-03-08 シェーリング コーポレイション ピロリジン、ピペリジンおよびピペラジン誘導体ならびにそれらの使用方法
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
EP2379564A1 (en) 2008-12-19 2011-10-26 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
SG173639A1 (en) 2009-02-11 2011-09-29 Sunovion Pharmaceuticals Inc Histamine h3 inverse agonists and antagonists and methods of use thereof
FR2945289A1 (fr) 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
NZ597511A (en) 2009-06-19 2014-01-31 Abbvie Inc Diazahomoadamantane derivatives and methods of use thereof
KR102173836B1 (ko) 2009-09-11 2020-11-05 아이오니스 파마수티컬즈, 인코포레이티드 헌팅틴 발현의 조절
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
WO2011057204A2 (en) 2009-11-06 2011-05-12 The Johns Hopkins University Lrrk2-mediated neuronal toxicity
US8754220B2 (en) 2009-11-20 2014-06-17 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide M1 receptor positive allosteric modulators
KR20130088002A (ko) 2010-01-13 2013-08-07 재단법인 한국파스퇴르연구소 항-감염성 피리도(1,2-ａ)피리미딘
JP6018506B2 (ja) 2010-02-08 2016-11-02 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 対立遺伝子多様体の選択的低減
US20130059902A1 (en) 2010-02-08 2013-03-07 Isis Pharmaceuticals, Inc. Methods and compositions useful in treatment of diseases or conditions related to repeat expansion
US8957040B2 (en) 2010-02-08 2015-02-17 Isis Pharmaceuticals, Inc. Selective reduction of allelic variants
EP2575866A4 (en) 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
WO2012012467A2 (en) 2010-07-19 2012-01-26 Isis Pharmaceuticals, Inc. Modulation of nuclear-retained rna
WO2012019106A2 (en) 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
CN102617548A (zh) 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
WO2013019938A1 (en) 2011-08-02 2013-02-07 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as eaat2 activators
US10202599B2 (en) 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
EP2560008B1 (en) 2011-08-18 2016-11-30 Korea Institute of Science and Technology Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
EP2751269B1 (en) 2011-08-29 2016-03-23 Ionis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
US9662314B2 (en) 2011-10-21 2017-05-30 Tufts Medical Center, Inc. Compounds and methods for the treatment of muscular disease, and related screening methods
GB201119538D0 (en) 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
CA2856334A1 (en) 2011-11-28 2013-06-06 Christina Hebach Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
BR112014016287B1 (pt) 2011-12-30 2022-08-09 F. Hoffmann - La Roche Ag Composto e composição farmacêutica
CN104203239B (zh) 2012-01-26 2017-09-08 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
TR201813877T4 (tr) 2012-02-10 2018-11-21 Hoffmann La Roche Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
US9371336B2 (en) 2012-03-01 2016-06-21 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
KR102109992B1 (ko) 2012-03-23 2020-05-13 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
SG10201704095UA (en) 2012-04-24 2017-06-29 Vertex Pharma Dna-pk inhibitors
AU2013289938A1 (en) 2012-07-13 2015-01-29 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
EP2906255B1 (en) 2012-10-12 2023-02-22 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
US20150275208A1 (en) 2012-10-12 2015-10-01 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US9227976B2 (en) * 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
CA2889494C (en) 2012-10-25 2018-12-18 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
JP6255711B2 (ja) 2012-11-01 2018-01-10 株式会社リコー エレクトロクロミック化合物、エレクトロクロミック組成物及び表示素子
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
WO2014121287A2 (en) 2013-02-04 2014-08-07 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
CN105026398B (zh) 2013-03-05 2018-05-18 默克专利股份公司 用于治疗疾病诸如癌症的三唑并[4,5-d]嘧啶衍生物
BR112015028475A2 (pt) 2013-05-14 2017-07-25 Hoffmann La Roche novos aza-oxo-indois para o tratamento ou profilaxia de infecção virótica respiratória sincitial
CN105358151B (zh) 2013-06-25 2019-04-12 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的化合物
EA030631B1 (ru) 2013-07-31 2018-09-28 Новартис Аг 1,4-дизамещенные аналоги пиридазинхинолина и способы лечения состояний, связанных с smn-дефицитом
WO2015024876A2 (en) 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Screening method
WO2015105657A1 (en) 2013-12-19 2015-07-16 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
WO2015095449A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
WO2015095446A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
EP3087067B1 (en) 2013-12-26 2018-10-24 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
AU2015207773B2 (en) 2014-01-16 2021-06-17 Wave Life Sciences Ltd. Chiral design
EP3094629B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
AR099134A1 (es) 2014-01-24 2016-06-29 Hoffmann La Roche Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
ES2850999T3 (es) 2014-03-14 2021-09-02 Raqualia Pharma Inc Derivados de azaespiro como antagonistas de TRPM8
CA2942975C (en) 2014-03-19 2023-08-29 Amydis Diagnostics, Inc. Substituted acrylamide and substituted ethenesulfonamide derivatives and pharmaceutical compositions thereof useful as amyloid targeting agents
HRP20230637T1 (hr) 2014-05-15 2023-09-29 F. Hoffmann - La Roche Ag Postupak za proizvodnju spojeva korisnih za liječenje spinalne mišićne atrofije
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
EP3157875A2 (en) 2014-06-17 2017-04-26 Novozymes A/S Biological phosphorus removal from wastewater
KR102565544B1 (ko) 2014-06-25 2023-08-10 에프. 호프만-라 로슈 아게 척수성 근위축증을 치료하기 위한 이미다조[1,2-a]피라진-1일-벤즈아마이드 화합물
CN107207526A (zh) 2014-12-02 2017-09-26 拜耳作物科学股份公司 作为害虫防治剂的双环化合物
PT3237618T (pt) 2014-12-24 2019-07-04 Uniqure Ip Bv Supressão do gene huntingtina induzida por arni
WO2016115434A1 (en) 2015-01-16 2016-07-21 The General Hospital Corporation Compounds for improving mrna splicing
EP3256126B1 (en) 2015-02-09 2024-03-27 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
GB201502567D0 (en) 2015-02-16 2015-04-01 Sentinel Oncology Ltd Pharmaceutical compounds
CN112679467A (zh) 2015-03-11 2021-04-20 Fmc公司 杂环取代的二环唑杀有害生物剂
GB201506933D0 (en) 2015-04-23 2015-06-10 Sentinel Oncology Ltd Pharmaceutical compounds
WO2016184832A1 (en) 2015-05-20 2016-11-24 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
WO2016196386A1 (en) 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US10226448B2 (en) * 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
JP2018533594A (ja) 2015-11-12 2018-11-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 筋萎縮性側索硬化症を処置するための化合物
WO2017080967A1 (en) 2015-11-12 2017-05-18 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
US10383867B2 (en) 2015-11-28 2019-08-20 Russell Dahl Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
LT3386511T (lt) * 2015-12-10 2021-08-25 Ptc Therapeutics, Inc. Hantingtono ligos gydymo būdai
US10526345B2 (en) 2016-04-08 2020-01-07 Mankind Pharma Ltd. Compounds as GPR119 agonists
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
JP7044375B2 (ja) 2016-05-31 2022-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｐｔｐｎ１１の複素環式阻害剤
US20190264267A1 (en) 2016-07-25 2019-08-29 Wave Life Sciences Ltd. Phasing
TW201819386A (zh) * 2016-10-24 2018-06-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
EP3606562A4 (en) 2017-04-03 2020-11-11 Acceleron Pharma Inc. COMPOSITIONS AND METHODS OF TREATMENT OF SPINAL MUSCLE ATROPHY
US11591336B2 (en) * 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
EP3645121A4 (en) 2017-06-28 2021-03-17 PTC Therapeutics, Inc. HUNTINGTON'S DISEASE TREATMENT METHODS
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
BR122020005073A2 (pt) 2017-08-04 2020-10-13 Skyhawk Therapeutics, Inc. Composto, composição farmacêutica e uso do composto
US20200392161A1 (en) 2018-02-21 2020-12-17 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
EP3768680A1 (en) 2018-03-21 2021-01-27 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
BR112020019385A2 (pt) 2018-03-21 2021-03-30 Relay Therapeutics, Inc. Inibidores de shp2 fosfatase e métodos de uso dos mesmos
US20210009590A1 (en) 2018-03-27 2021-01-14 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
SG11202012869SA (en) 2018-06-27 2021-01-28 Ptc Therapeutics Inc Heteroaryl compounds for treating huntington's disease
EP3814360A1 (en) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
EP3814357B1 (en) 2018-06-27 2024-05-01 PTC Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
CN113840602A (zh) 2019-03-15 2021-12-24 斯基霍克疗法公司 用于校正异常剪接的组合物和方法
EP4219466A1 (en) 2019-05-13 2023-08-02 PTC Therapeutics, Inc. Compunds for treating huntington's disease
WO2021007378A1 (en) 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease
KR20220093335A (ko) 2019-11-01 2022-07-05 노파르티스 아게 헌팅턴병의 진행을 늦추는 치료를 위한 스플라이싱 조절제의 용도
EP4132923A1 (en) 2020-04-09 2023-02-15 PTC Therapeutics, Inc. Compounds for treating huntington's disease
IL302839A (en) 2020-11-12 2023-07-01 Ptc Therapeutics Inc A novel RNA transcript
AR126612A1 (es) 2021-07-30 2023-10-25 Ptc Therapeutics Inc Compuestos de heteroarilo para el tratamiento de la enfermedad de huntington

Also Published As

Publication number Publication date
CL2020003378A1 (es) 2021-06-18
SG11202012674PA (en) 2021-01-28
US11858941B2 (en) 2024-01-02
MX2020014098A (es) 2021-05-27
CL2022003434A1 (es) 2023-06-02
AU2019294478B2 (en) 2023-03-23
US20210238186A1 (en) 2021-08-05
CO2020016285A2 (es) 2021-01-18
WO2020005873A1 (en) 2020-01-02
BR112020026545A2 (pt) 2021-03-23
JP2021528467A (ja) 2021-10-21
AR119651A1 (es) 2022-01-05
CA3103976A1 (en) 2020-01-02
AU2023203241A1 (en) 2023-06-15
KR20210042265A (ko) 2021-04-19
EP3814357B1 (en) 2024-05-01
IL279688A (en) 2021-03-01
EA202092896A1 (ru) 2021-04-13
CN112654625A (zh) 2021-04-13
CL2021003022A1 (es) 2022-07-01
JP7421507B2 (ja) 2024-01-24
EP3814357A1 (en) 2021-05-05
AU2019294478A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
PE20211378A1 (es) Compuestos heterociclicos y de heteroarilo para tratar la enfermedad de huntington
PE20220133A1 (es) Inhibidores del inflamasoma nlrp3
PE20211585A1 (es) Agente profilactico o terapeutico para atrofia muscular espinal
PE20142364A1 (es) Compuestos para tratar atrofia muscular espinal
ECSP077336A (es) Control de parásitos en animales mediante el uso de nuevos derivados de trifluorometansulfonanilida oxima éter
AR074459A1 (es) Pirrolopirazinil-ureas utiles para el tratamiento de enfermedades autoinmunes e inflamatorias.
PE20170683A1 (es) Triazolo[4,5-d]pirimidinas como agonistas del receptor canabinoide 2
PE20211275A1 (es) Compuestos heterociclicos antihelminticos
PE20020915A1 (es) Diaminotiazoles como inhibidores de quinasas dependientes de ciclina
EA200970140A1 (ru) Производные и аналоги n-этилхинолонов и n-этилазахинолонов
PE20070520A1 (es) Compuestos heterociclicos fusionados como moduladores de cinasa
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20070517A1 (es) Derivados de imidazol como agentes inhibidores de la sintasa de aldosterona y aromatasa
UY29177A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
ECSP045253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
HN2011000876A (es) Inhibidores de las enzimas de proteina cinaza activadas por mitogeno p38
UY31072A1 (es) Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
AR080699A1 (es) Pirrolopirazinas como inhibidores de jak y syk
PE20212090A1 (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso para tratar el cancer
PE20060524A1 (es) Compuestos heterociclico fusionados como intermediarios en la preparacion de pirrolotriazinas inhibidoras de cinasa
CR11517A (es) Derivados bis-(sulfonilamino) para uso en terapia
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
NI200600094A (es) Compuesto heterociclicos fusionados
PE20141557A1 (es) Derivado de pirazoloquinolina